179 related articles for article (PubMed ID: 22164234)
1. Both hMutSα and hMutSß DNA mismatch repair complexes participate in 5-fluorouracil cytotoxicity.
Tajima A; Iwaizumi M; Tseng-Rogenski S; Cabrera BL; Carethers JM
PLoS One; 2011; 6(12):e28117. PubMed ID: 22164234
[TBL] [Abstract][Full Text] [Related]
2. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance.
Tajima A; Hess MT; Cabrera BL; Kolodner RD; Carethers JM
Gastroenterology; 2004 Dec; 127(6):1678-84. PubMed ID: 15578504
[TBL] [Abstract][Full Text] [Related]
3. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.
de Castro E Gloria H; Jesuíno Nogueira L; Bencke Grudzinski P; da Costa Ghignatti PV; Guecheva TN; Motta Leguisamo N; Saffi J
BMC Cancer; 2021 Apr; 21(1):448. PubMed ID: 33888065
[TBL] [Abstract][Full Text] [Related]
4. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Park JM; Huang S; Tougeron D; Sinicrope FA
PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
[TBL] [Abstract][Full Text] [Related]
5. DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells.
Iwaizumi M; Tseng-Rogenski S; Carethers JM
Cancer Biol Ther; 2011 Oct; 12(8):756-64. PubMed ID: 21814034
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
Hamaya Y; Guarinos C; Tseng-Rogenski SS; Iwaizumi M; Das R; Jover R; Castells A; Llor X; Andreu M; Carethers JM
PLoS One; 2015; 10(5):e0127591. PubMed ID: 25996601
[TBL] [Abstract][Full Text] [Related]
7. Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity.
Iwaizumi M; Tseng-Rogenski S; Carethers JM
Mutat Res; 2013; 747-748():19-27. PubMed ID: 23643670
[TBL] [Abstract][Full Text] [Related]
8. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status.
Adamsen BL; Kravik KL; De Angelis PM
Int J Oncol; 2011 Sep; 39(3):673-82. PubMed ID: 21674128
[TBL] [Abstract][Full Text] [Related]
9. Mismatch repair proficiency and in vitro response to 5-fluorouracil.
Carethers JM; Chauhan DP; Fink D; Nebel S; Bresalier RS; Howell SB; Boland CR
Gastroenterology; 1999 Jul; 117(1):123-31. PubMed ID: 10381918
[TBL] [Abstract][Full Text] [Related]
10. Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner.
Chung H; Chaudhry J; Lopez CG; Carethers JM
Cancer Biol Ther; 2010 Dec; 10(11):1147-56. PubMed ID: 20930505
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells.
Fujita H; Kato J; Horii J; Harada K; Hiraoka S; Shiraha H; Sakaguchi K; Shiratori Y
Oncol Rep; 2007 Nov; 18(5):1129-37. PubMed ID: 17914563
[TBL] [Abstract][Full Text] [Related]
12. Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures.
Shakibaei M; Buhrmann C; Kraehe P; Shayan P; Lueders C; Goel A
PLoS One; 2014; 9(1):e85397. PubMed ID: 24404205
[TBL] [Abstract][Full Text] [Related]
13. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
14. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
Arnold CN; Goel A; Boland CR
Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
[TBL] [Abstract][Full Text] [Related]
15. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line.
Yoo BC; Jeon E; Hong SH; Shin YK; Chang HJ; Park JG
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4176-84. PubMed ID: 15217955
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic implications in microsatellite unstable colorectal cancer.
Jo WS; Carethers JM
Cancer Biomark; 2006; 2(1-2):51-60. PubMed ID: 17192059
[TBL] [Abstract][Full Text] [Related]
18. Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells.
Paul S; Chatterjee S; Sinha S; Dash SR; Pradhan R; Das B; Goutam K; Kundu CN
Expert Opin Ther Targets; 2023; 27(10):999-1015. PubMed ID: 37787493
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.
Geng L; Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
PLoS One; 2011; 6(12):e28862. PubMed ID: 22194930
[TBL] [Abstract][Full Text] [Related]
20. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity.
Kothandapani A; Sawant A; Dangeti VS; Sobol RW; Patrick SM
Nucleic Acids Res; 2013 Aug; 41(15):7332-43. PubMed ID: 23761438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
